BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
An Open Label, Long Term Safety Trial of BI 655130 (SPESOLIMAB) Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials An Open Label, Long Term Safety Trial of BI 655130 (SPESOLIMAB) Treatment in Patients With Moderate ...
Colitis, Ulcerative
Drug: Spesolimab IV infusion;Drug: Spesolimab SC solution for injection
Boehringer Ingelheim
NULL
Active, not recruiting
18 Years
N/A
All
79
Phase 2
United States;Austria;Belgium;Canada;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;United Kingdom United States;Austria;Belgium;Canada;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federatio ...